2026 Renier J. Brentjens: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	84	1336	1217	686	612	325	41359
Medicine	84	14841	13967	7502	6942	327	41448

Overview

Renier J. Brentjens is affiliated with the Roswell Park Cancer Institute in the United States. Their research primarily centers on the field of medicine, with a strong focus on oncology and immunology. The scientist's body of work spans molecular biology, genetics, and electrical and electronic engineering, demonstrating a multidisciplinary approach to biomedical challenges.

The main topics of Renier J. Brentjens' research include:

CAR-T cell therapy research
Immune Cell Function and Interaction
Viral Infectious Diseases and Gene Expression in Insects
Immunotherapy and Immune Responses
Virus-based gene therapy research
Nanowire Synthesis and Applications
Cancer Immunotherapy and Biomarkers

Among their recent publications are significant contributions to the field of CAR-T cell therapy and immunotherapy:

"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab" (2021, Cancer Discovery)
"GPRC5D-Targeted CAR T Cells for Myeloma" (2022, New England Journal of Medicine)
"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion" (2022, Nature Reviews Clinical Oncology)
"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy" (2022, Nature Medicine)
"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies" (2020, Blood Advances)

Renier J. Brentjens has a consistent publication record in high-impact journals and specialized venues including:

Blood
Cancer Immunology Research
Nature Medicine
Blood Advances
Journal for ImmunoTherapy of Cancer

The scientist collaborates frequently with peers such as Jae H. Park, Isabelle Rivière, Michel Sadelain, Sergio Giralt, and Craig S. Sauter, reflecting an active engagement in advancing cancer immunotherapy research through teamwork.

Best Publications

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido

2920
Citations
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park;Isabelle Rivière;Mithat Gonen;Xiuyan Wang

2676
Citations
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Renier J. Brentjens;Marco L. Davila;Isabelle Riviere;Jae Park

2437
Citations
The Basic Principles of Chimeric Antigen Receptor Design

Michel Sadelain;Renier Brentjens;Isabelle Rivière

1981
Citations
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Renier J. Brentjens;Isabelle Rivière;Jae H. Park;Marco L. Davila

1554
Citations
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Danny N. Khalil;Eric L. Smith;Renier J. Brentjens;Jedd D. Wolchok

1491
Citations
Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Sarwish Rafiq;Christopher S. Hackett;Renier J. Brentjens

1333
Citations
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

John Maher;Renier J Brentjens;Gertrude Gunset;Isabelle Rivière

1259
Citations
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Renier J. Brentjens;Jean Baptiste Latouche;Elmer Santos;Francesc Marti

987
Citations
Toxicity and management in CAR T-cell therapy.

Challice L Bonifant;Hollie J Jackson;Renier J Brentjens;Kevin J Curran

965
Citations
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

Hollie J. Pegram;James C. Lee;Erik G. Hayman;Gavin H. Imperato

898
Citations
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Bianca D. Santomasso;Jae H. Park;Darin Salloum;Isabelle Riviere

870
Citations
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Sarwish Rafiq;Oladapo O Yeku;Hollie J Jackson;Terence J Purdon

809
Citations
The promise and potential pitfalls of chimeric antigen receptors

Michel Sadelain;Renier Brentjens;Isabelle Rivière

791
Citations
Targeting tumours with genetically enhanced T lymphocytes

Michel Sadelain;Isabelle Rivière;Renier Brentjens

786
Citations
Driving CAR T-cells forward

Hollie J. Jackson;Sarwish Rafiq;Renier J. Brentjens

725
Citations
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts

Renier J. Brentjens;Elmer Santos;Yan Nikhamin;Raymond Yeh

718
Citations
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

Renier Brentjens;Raymond Yeh;Yvette Bernal;Isabelle Riviere

604
Citations
Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes

Michael R. McDevitt;Debjit Chattopadhyay;Barry J. Kappel;Jaspreet Singh Jaggi

558
Citations
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

Prasad S. Adusumilli;Marjorie G. Zauderer;Isabelle Rivière;Stephen B. Solomon

519
Citations
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Daniel Hollyman;Jolanta Stefanski;Mark Przybylowski;Shirley Bartido

473
Citations

Frequent Co-Authors

Michel Sadelain Columbia University

Isabelle Riviere Memorial Sloan Kettering Cancer Center

Sergio Giralt Memorial Sloan Kettering Cancer Center

Miguel-Angel Perales Memorial Sloan Kettering Cancer Center

Nancy A. Kernan Memorial Sloan Kettering Cancer Center

Richard J. O'Reilly Memorial Sloan Kettering Cancer Center

David A. Scheinberg Memorial Sloan Kettering Cancer Center

Marcel R.M. van den Brink Memorial Sloan Kettering Cancer Center

Mithat Gonen Memorial Sloan Kettering Cancer Center

Steven M. Larson Memorial Sloan Kettering Cancer Center

External Links

Personal website of Renier J. Brentjens

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to diverse healthcare careers, many of which can be enhanced through online education. For nurses and healthcare professionals, pursuing advanced degrees is a strategic way to deepen expertise and improve earning potential. Interested students can explore online accelerated nursing programs for non nurses, which offer a fast-track route into the nursing field without prior nursing experience.

For registered nurses ready to advance, accelerated RN to NP programs provide a compact timeframe to become nurse practitioners, significantly expanding career options. Additionally, existing family nurse practitioners (FNPs) may consider gaining specialized skills with an acute care certification for FNP, adapting their practice to acute and critical care settings.

Understanding salary prospects can help shape career decisions. Exploring the DNP salary across different states reveals variations that impact financial planning and job market choices. Together, these pathways reflect the evolving landscape of healthcare careers linked to immunology expertise.